Fate Therapeutics Inc

NASDAQ:FATE   4:00:00 PM EDT
20.82
+0.98 (+4.94%)
7:38:02 PM EDT: $20.82 0.00 (0.00%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)2.02B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$19.49 Million
Adjusted EPS-$0.88
See more estimates
10-Day MA$20.24
50-Day MA$20.91
200-Day MA$27.71
See more pivots

Fate Therapeutics Inc Stock, NASDAQ:FATE

12278 Scripps Summit Drive, Suite 200, San Diego, California 92131
United States of America
Phone: +1.858.875.1800
Number of Employees: 449

Description

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.